Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Currency in USD	2025
Operating Income	-393.34 Million
Income Before Tax	-359.64 Million
Income Tax Expense	1.00 Thousand
Net Income	-359.64 Million
Eps	-3.19
Epsdiluted	-3.19
Weighted Average Shs Out	112.67 Million
Weighted Average Shs Out Dil	112.67 Million
Research And Development Expenses	344.95 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	431.00 Thousand
Interest Expense	N/A
Interest Income	33.70 Million
Net Interest Income	33.65 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	-392.91 Million
Source	edgar
Ebit	-393.34 Million

Viking Therapeutics, Inc. Annual Reports (10-K)